These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 21077963)

  • 21. Apoplexy of clinically silent pituitary adenoma during prostate cancer treatment with LHRH analog.
    Błaut K; Wiśniewski P; Syrenicz A; Sworczak K
    Neuro Endocrinol Lett; 2006 Oct; 27(5):569-72. PubMed ID: 17159826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Granulomas induced by subcutaneous injection of a luteinizing hormone-releasing hormone analog: a case report and review of the literature.
    Watanabe T; Yamada N; Yoshida Y; Yamamoto O
    J Cutan Pathol; 2010 Oct; 37(10):1116-8. PubMed ID: 19863702
    [No Abstract]   [Full Text] [Related]  

  • 23. Successful recovery from interstitial pneumonitis, induced by bicalutamide and leuprorelin acetate given as treatment for prostate cancer.
    Shioi K; Sakai N; Yoshida M; Nakamura M
    Hinyokika Kiyo; 2005 Mar; 51(3):211-4. PubMed ID: 15852680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Giant subcutaneous hematoma with hemorrhagic shock induced by goserelin acetate injection for prostate cancer : report of a case].
    Tashiro K; Kimura S; Naruoka T; Furuta N; Egawa S
    Hinyokika Kiyo; 2014 Sep; 60(9):455-8. PubMed ID: 25293802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate cancer--the therapeutic challenge of locally advanced disease.
    Blasko JC; Lange PH
    N Engl J Med; 1997 Jul; 337(5):340-1. PubMed ID: 9233872
    [No Abstract]   [Full Text] [Related]  

  • 26. Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer--a pilot study.
    Sugiono M; Winkler MH; Okeke AA; Benney M; Gillatt DA
    Prostate Cancer Prostatic Dis; 2005; 8(1):91-4. PubMed ID: 15711607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Goserelin (Zoladex) or orchiectomy in metastatic prostate cancer? A quality of life and cost-effectiveness analysis.
    Nygård R; Norum J; Due J
    Anticancer Res; 2001; 21(1B):781-8. PubMed ID: 11299844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
    BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severe flare-up in a prostate cancer patient treated with luteinizing hormone-releasing hormone analogue depot.
    Shimizu T; Shibata Y; Uchida T; Satoh J
    Hinyokika Kiyo; 1993 Oct; 39(10):953-5. PubMed ID: 8266863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Serum concentrations of flutamide and goserelin in a prostate cancer patient with obstructive nephropathy: a case report].
    Nagayoshi J; Higashi T; Maruyama Y
    Hinyokika Kiyo; 1999 Aug; 45(8):543-6. PubMed ID: 10500960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer?
    Pollack A; Horwitz EM
    Nat Clin Pract Oncol; 2005 Jan; 2(1):12-3. PubMed ID: 16264846
    [No Abstract]   [Full Text] [Related]  

  • 33. Severe symptomatic osteoporosis in patients on androgen deprivation therapy for prostatic carcinoma.
    Paterson CR; Mole PA
    Scand J Urol Nephrol; 2002; 36(4):314-6. PubMed ID: 12201927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pituitary apoplexy induced by triptorelin in patient with prostate cancer.
    Guerrero-Pérez F; Marengo AP; Planas-Vilaseca A; Flores-Escobar V; Villabona-Artero C
    Endocrinol Nutr; 2015 Oct; 62(8):411-2. PubMed ID: 26184059
    [No Abstract]   [Full Text] [Related]  

  • 35. Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study.
    Jenkins VA; Bloomfield DJ; Shilling VM; Edginton TL
    BJU Int; 2005 Jul; 96(1):48-53. PubMed ID: 15963119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long term zoledronic acid during androgen blockade for prostate cancer.
    Casey R; Gesztesi Z; Rochford J
    Can J Urol; 2010 Jun; 17(3):5170-7. PubMed ID: 20566009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Ice application for reducing pain associated with goserelin acetate injection].
    Ishii K; Nagata C; Koshizaki E; Nishiuchi S
    Gan To Kagaku Ryoho; 2013 Oct; 40(10):1361-3. PubMed ID: 24105059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Skin reaction induced by subcutaneous injection of LH-RH analogue].
    Segawa N; Nishida T; Hamada S; Azuma H; Katsuoka Y; Nozaki K; Tsuji M
    Hinyokika Kiyo; 2007 Oct; 53(10):695-8. PubMed ID: 18018584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Coping and health-related quality of life in men with prostate cancer randomly assigned to hormonal medication or close monitoring.
    Green HJ; Pakenham KI; Headley BC; Gardiner RA
    Psychooncology; 2002; 11(5):401-14. PubMed ID: 12228873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RTOG study shows improved survival for prostate cancer patients given adjuvant goserelin.
    Oncology (Williston Park); 2005 Aug; 19(9):1142. PubMed ID: 16402596
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.